CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $3.22B, above the global median of $1.15B
- PositionGross margin is 100%, higher than 95% of its Biotechnology peers (median 67.1%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.46TKRW3.22B · vs all stocks (USD)
Revenue (TTM)
90.32BKRW65.08M · vs all stocks (USD)
Profit Margin
-26.72%vs Biotechnology peers
Beta
0.2610xvs all stocks
52-Week Change
-1.73%vs all stocks
Market Capitalization
4.46TKRW3.22B · vs all stocks (USD)
Enterprise Value
4.34TKRW3.13B · vs all stocks (USD)
Forward P/E
372.00xvs Biotechnology peers
Price to Sales (TTM)
49.65xvs Biotechnology peers
Price to Book (MRQ)
24.13xvs Biotechnology peers
Enterprise to Revenue
48.02xvs Biotechnology peers
Enterprise to EBITDA
-175.45xvs Biotechnology peers
Gross Margin
100.00%vs Biotechnology peers
Profit Margin
-26.72%vs Biotechnology peers
Operating Margin
-131.13%vs Biotechnology peers
Return on Assets (TTM)
-7.02%vs Biotechnology peers
Return on Equity (TTM)
-14.95%vs Biotechnology peers
Revenue (TTM)
90.32BKRW65.08M · vs all stocks (USD)
Revenue per Share (TTM)
1.70KKRWUpdated Aug 19, 2026Quarterly Revenue Growth
506.80%vs Biotechnology peers
Gross Profit (TTM)
90.21BKRW65.00M · vs all stocks (USD)
EBITDA (TTM)
-24.72BKRW-17.81M · vs all stocks (USD)
Net Income (TTM)
-24.14BKRW-17.39M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
506.83%vs Biotechnology peers
Operating Cash Flow (TTM)
19.95BKRW14.38M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
7.28BKRW5.25M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
1.98BKRWFY2025 · Dec 31, 2025Revenue
79.35BKRWFY2025 · Dec 31, 2025Gross Profit
79.35BKRWFY2025 · Dec 31, 2025Operating Income
-40.28BKRW-29.02M · vs all stocks (USD)
Pre-tax Income
-37.88BKRWFY2025 · Dec 31, 2025Net Income
-37.88BKRWFY2025 · Dec 31, 2025EBIT
-36.88BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-33.78BKRWFY2025 · Dec 31, 2025Research & Development
93.01BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
14.49BKRWFY2025 · Dec 31, 2025Other Operating Expenses
8.30MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
2.98BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
993.05MKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-37.88BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
71.00MKRWFY2025 · Dec 31, 2025Operating Cash Flow
-41.63BKRWFY2025 · Dec 31, 2025Free Cash Flow
-61.66BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
111.98BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-37.88BKRWFY2025 · Dec 31, 2025Stock-based Compensation
5.44BKRWFY2025 · Dec 31, 2025Other Non-cash Items
-1.95BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-59.38BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
52.14BKRWFY2025 · Dec 31, 2025Capital Expenditures
-20.03BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-605.69MKRWFY2025 · Dec 31, 2025Sale of Investments
81.80BKRWFY2025 · Dec 31, 2025Other Investing Activity
752.77MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
62.52BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
12.00BKRWFY2025 · Dec 31, 2025Other Financing Charges
-26.18MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
33.20BKRWFY2025 · Dec 31, 2025Shares Outstanding
55.99MSharesUpdated Aug 19, 2026Float Shares
41.56MSharesUpdated Aug 19, 2026% Held by Insiders
24.52%vs all stocks
% Held by Institutions
13.82%vs all stocks
Total Cash (MRQ)
188.79BKRW136.03M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.37KKRWUpdated Aug 19, 2026Total Debt (MRQ)
55.49BKRW39.98M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3027xvs Biotechnology peers
Current Ratio (MRQ)
1.70xvs Biotechnology peers
Book Value per Share (MRQ)
3.30KKRWUpdated Aug 19, 2026Total Assets
280.93BKRW202.43M · vs all stocks (USD)
Total Current Assets
176.05BKRWFY2025 · Dec 31, 2025Total Liabilities
124.24BKRWFY2025 · Dec 31, 2025Total Non-current Assets
104.88BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
739.10MKRWFY2025 · Dec 31, 2025Total Current Liabilities
123.50BKRWFY2025 · Dec 31, 2025Cash
111.98BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
111.98BKRWFY2025 · Dec 31, 2025Other Short-term Investments
2.96BKRWFY2025 · Dec 31, 2025Accounts Receivable
59.11BKRWFY2025 · Dec 31, 2025Short-term Debt
55.14BKRWFY2025 · Dec 31, 2025Other Current Liabilities
-300.00KRWFY2025 · Dec 31, 2025Long-term Debt
189.13MKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
-20.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
27.56BKRWFY2025 · Dec 31, 2025Retained Earnings
-436.22BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
156.70BKRW112.91M · vs all stocks (USD)
52-Week Low
59.80KKRWUpdated Aug 19, 202652-Week High
257.50KKRWUpdated Aug 19, 202652-Week Change
-1.73%vs all stocks
Beta
0.2610xvs all stocks
50-Day MA
85.55KKRWUpdated Aug 19, 2026200-Day MA
148.03KKRWUpdated Aug 19, 2026Avg 10-Day Volume
351.75KSharesUpdated Aug 19, 2026Avg 30-Day Volume
361.40KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-734.00KRWUpdated Aug 19, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 100%, higher than 95% of its Biotechnology peers (median 67.1%)Significant
Gross margin: 1.00Industry median: 0.67Industry P95: 1.00Peers compared: 261
Price-to-book is 24.13×, higher than 95% of its Biotechnology peers (median 2.97×)Significant
Price-to-book: 24.13Industry median: 2.97Industry P95: 23.50Peers compared: 261
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 1.00Profit Margin: -0.27
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 5.13
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $3.22B, above the global median of $1.15BNotable
Market cap (USD): 3,215,283,409.241Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Betta Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Integer Holdings Corporation
Tier 1ProductionApproval-Gated PipelineRule
Jilin Aodong Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wockhardt Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hybio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
BioArctic AB
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Haoyuan Chemexpress Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lepu Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chengdu Kanghong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Harbin Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Shenzhen JDD Tech New Material Co., Ltd.
4 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownIndustry-Benchmarked ROA and Margin Elevated
Orum Therapeutics Inc.
4 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownIndustry-Benchmarked ROA and Margin Elevated
Hangzhou XZB Tech Co., Ltd.
4 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownIndustry-Benchmarked ROA and Margin Elevated